INDUCTION OF CYP1A IN THE BEAGLE DOG BY AN INHIBITOR OF KINASE INSERT DOMAIN-CONTAINING RECEPTOR: DIFFERENTIAL EFFECTS IN VITRO AND IN VIVO ON MRNA AND FUNCTIONAL ACTIVITY

Christopher R. Gibson(United States Military Academy), Thomas H. Rushmore(Merck Canada Inc. (Canada)), Catherine Boothe-Genthe(Merck Biopharma Co., Ltd. (Japan)), Conrad E. Raab(Merck & Co., Inc., Rahway, NJ, USA (United States)), Raju Subramanian(Gilead Sciences (United States)), Thomas A. Baillie(University of Washington), Paul Krolikowski(Merck Biopharma Co., Ltd. (Japan)), Karen Richards(Merck Biopharma Co., Ltd. (Japan)), Aimee Michael(Merck Biopharma Co., Ltd. (Japan)), Minh Thu Luu(Merck Biopharma Co., Ltd. (Japan)), Cheri M. Brown(Merck Biopharma Co., Ltd. (Japan)), Edward J. Carlini(Merck & Co., Inc., Rahway, NJ, USA (United States)), Jennifer K. Adelsberger(Merck Biopharma Co., Ltd. (Japan)), Mona Parikh(Merck Biopharma Co., Ltd. (Japan)), Kimberly Michel(Merck Biopharma Co., Ltd. (Japan)), Rominder Singh, A. David Rodrigues(Bristol-Myers Squibb (Germany)), Charles C. Lin(Merck Biopharma Co., Ltd. (Japan)), Janice Brunner(Merck Biopharma Co., Ltd. (Japan)), Patrice A. Ciecko(United States Military Academy)
Drug Metabolism and Disposition
April 16, 2005
Cited by 6


Related Papers